Skip to main content
Find more clinical trials

Insulin Nasal Spray To Reduce Alzheimer's Disease Risk in African Americans

Start: June 17, 2021
End: December 2023
Enrollment: 40

What Is This Study About?

This study will investigate the effect of insulin, by nasal spray, on food intake and Alzheimer's disease risk factors, such as obesity, in African Americans. Participants will be randomly assigned to receive either insulin or a placebo by nasal spray before eating a prepared meal. All participants will also provide blood samples to test for APOE, a gene associated with Alzheimer's disease risk. The study involves four visits to the clinic with three provided lunches and some take-home meals. Researchers will measure food intake, hunger, memory and concentration, bone density, muscle, and body fat.

Do I Qualify To Participate in This Study?

Minimum Age: 45 Years

Maximum Age: 65 Years

Must have:

  • Self-identify as African American
  • Speak and read English

Must NOT have:

  • Diagnosed with type 1 or 2 diabetes
  • Pregnant or attempting to become pregnant
  • History of sensitivity to glutaraldehyde

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Who Is the General Study Contact?

For more information and to enroll, visit the FIINAAL study website.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Pennington Biomedical Research Center

Collaborator Sponsor

  • Nutrition Obesity Research Center

Source: ClinicalTrials.gov ID: NCT04739371